Japan's Rule-Relaxation Leads Drug, Device Makers To Expand Operations
This article was originally published in PharmAsia News
Japan's move to ease its drug-regulation process is leading foreign makers of drugs and medical devices to beef up their operations in the country to get an edge in the world's second-largest market in both sectors.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
President Trump on 27 March signed into law a $2.2tn COVID-19 stimulus package that provides $80m to the US Food and Drug Administration for emergency use authorization of medical products. See what FDA commissioner Stephen Hahn said about it here.
"We're particularly concerned about the health care area right now because obviously that's driving everything now," says Tennessee AG Herbert Slatery III. He and CRN CEO Steve Mister spoke with HBW Insight about regulation of the consumer health marketplace with FDA suspending inspections of facilities operated by businesses manufacturing and marketing products subject to its oversight.